Related Experiment Video
Updated: Jul 16, 2026
07:42
Magnetic Levitation Coupled with Portable Imaging and Analysis for Disease Diagnostics
Published on: February 19, 2017
Sickle cell disease: current clinical management.
1Cardeza Foundation for Hematologic Research, Philadelphia PA 19107, USA.
Seminars in Hematology
|October 18, 2001
Summary
Sickle cell disease (SCD) presents with varied symptoms affecting daily life. This review focuses on managing SCD pain and organ failure.
Area of Science:
- Hematology
- Genetics
- Internal Medicine
Background:
- Sickle cell disease (SCD) exhibits significant variability in clinical presentation among patients.
- The diverse phenotype of SCD impacts multiple life domains, including social, familial, educational, and professional aspects.
- Clinical manifestations are categorized into anemia, pain, and end-organ failure.
Purpose of the Study:
- To review the pathophysiology and management strategies for sickle cell pain.
- To discuss the management of end-organ failure in sickle cell disease.
- To provide a comprehensive overview of sickle cell disease manifestations and treatments.
Main Methods:
- Literature review focusing on pathophysiology and clinical management.
- Synthesis of current research on sickle cell pain management.
- Analysis of treatment approaches for organ failure in SCD.
Main Results:
- Sickle cell pain and end-organ failure are primary complications requiring targeted management.
- Understanding pathophysiology is crucial for effective treatment of SCD complications.
- Multifaceted management strategies are essential for improving patient outcomes.
Conclusions:
- Effective management of sickle cell disease requires addressing pain and preventing/treating organ failure.
- Further research into SCD pathophysiology can lead to improved therapeutic interventions.
- A holistic approach is necessary to mitigate the impact of SCD on patients' lives.
More Related Videos
Related Concept Videos
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
01:29Chronic Obstructive Pulmonary Disease-V: Management
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
01:20Rheumatic Heart Disease IV: Nursing Management
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...